Pricing Log in Create free account
Friday 6 November 2026 Export RXRX’s income statement to Excel — free account

Recursion Pharmaceuticals, Inc.

RXRX Healthcare Biotechnology

Recursion Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $74.7 million, up 26.9% from fiscal 2024.

Revenue
+258.5%
EPS
+39.1%
Free cash flow
+33.8%
Total debt
−99.2%

Quarter to September 2026, against a year earlier

3.59 0.09 +2.57%
Market cap
$2.2B
P/E
0.0×
Fwd P/E
−4.6×
Dividend yield
—
F-score
3/9
Altman Z
0.37
Beneish M
−1.72
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Recursion Pharmaceuticals, Inc. (RXRX) Net margin

Alert me on Net margin

Recursion Pharmaceuticals, Inc.'s net margin over the twelve months to 30 September 2026 was −697.1%, up 166.2 percentage points from fiscal 2025 (−863.4%). Over the past ten years it has ranged from −2,668.4% (fiscal 2019) to −601.1% (fiscal 2022); the current reading is higher than 64% of that period. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.

Net margin, annual

Embed this chart

Annual newest first

Period Net margin Change (points)
FY2025 −863.4% (75.33)
FY2024 −788.0% (52.03)
FY2023 −736.0% (134.94)
FY2022 −601.1% 0.00
FY2022 −601.1% 1,231.13
FY2021 −1,832.2% 0.00
FY2021 −1,832.2% 363.83
FY2020 −2,196.0% 0.00
FY2020 −2,196.0% 472.34
FY2019 −2,668.4% 0.00

Quarterly newest first

Period Net margin Change (points)
Sep 2026 −641.6% 1,066.39
Jun 2026 −1,708.0% 107.55
Mar 2026 −1,815.6% (1,511.33)
Dec 2025 −304.2% 2,831.08
23 more quarters

Against its own ten years

Low −2,668.4% High −601.1%
Ten-year median −1,832.2%
Current reading's percentile 79

Net margin against peers

Company Net margin
ADMA ADMA Biologics Inc compare 35.1%
VCEL Vericel Corporation compare 10.3%
MBX MBX Biosciences, Inc. compare 0.00%
BHVN Biohaven Ltd. compare 0.00%
PHVS Pharvaris N.V. compare 0.00%
PVLA Palvella Therapeutics, Inc. compare 0.00%
RXRX Recursion Pharmaceuticals, Inc. −697.1%
NAMS NewAmsterdam Pharma Company N.V. compare −789.9%
CLDX Celldex Therapeutics, Inc. compare −33,883.8%
Biotechnology industry median 0.00%
Healthcare sector median 0.00%
Market median 1.06%

What Net margin is

Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.

Net Income Allotted to Shareholders ÷ Revenue

The full definition of Net margin →

More on RXRX